Roles of microRNAs in inflammatory bowel disease by 신재일 et al.





International Journal of Biological Sciences 
2021; 17(8): 2112-2123. doi: 10.7150/ijbs.59904 
Review 
Roles of microRNAs in inflammatory bowel disease 
HyunTaek Jung1*, Jae Seok Kim2*, Keum Hwa Lee3, Kalthoum Tizaoui4, Salvatore Terrazzino5, Sarah Cargnin5, 
Lee Smith6, Ai Koyanagi7,8, Louis Jacob7,9, Han Li10, Sung Hwi Hong1, Dong Keon Yon11, Seung Won Lee12, Min 
Seo Kim13, Paul Wasuwanich10, Wikrom Karnsakul14, Jae Il Shin3, Andreas Kronbichler15 
1. Yonsei University College of Medicine, Seoul, Republic of Korea. 
2. Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea. 
3. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. 
4. Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia. 
5. Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte 
Orientale, Novara, Italy. 
6. The Cambridge Centre for Sport and Exercise Science, Anglia Ruskin University, Cambridge, CB1 1PT, UK. 
7. Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, 08830 Barcelona, Spain. 
8. ICREA, Pg. Lluis Companys 23, 08010 Barcelona, Spain. 
9. Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78000 Versailles, France. 
10. University of Florida College of Medicine, Gainesville, FL 32610, USA. 
11. Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. 
12. Department of Data Science, Sejong University College of Software Convergence, Seoul, Republic of Korea. 
13. Korea University, College of Medicine, Seoul, Republic of Korea. 
14. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, USA. 
15. Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria. 
*These authors contributed equally to this work. 
 Corresponding author: Jae Il Shin, M.D., Ph.D. Address: 50 Yonsei-ro, Seodaemun-gu, C.P.O. Box 8044, Department of Pediatrics, Yonsei University College of Medicine, 
Seoul 03722, Republic of Korea. Tel: +82-2-2228-2050; Fax: +82-2-393-9118; E-mail: shinji@yuhs.ac. 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2021.02.28; Accepted: 2021.05.08; Published: 2021.05.17 
Abstract 
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly 
affects young people. IBD is associated with various gastrointestinal symptoms, and thus, affects the quality of 
life of patients. Currently, the pathogenesis of IBD is poorly understood. Although intestinal bacteria and host 
immune response are thought to be major factors in its pathogenesis, a sufficient explanation of their role in its 
pathophysiologic mechanism has not been presented. MicroRNAs (miRNAs), which are small RNA molecules 
that regulate gene expression, have gained attention as they are known to participate in the molecular 
interactions of IBD. Recent studies have confirmed the important role of miRNAs in targeting certain 
molecules in signaling pathways that regulate the homeostasis of the intestinal barrier, inflammatory reactions, 
and autophagy of the intestinal epithelium. Several studies have identified the specific miRNAs associated with 
IBD from colon tissues or serum samples of IBD patients and have attempted to use them as useful diagnostic 
biomarkers. Furthermore, some studies have attempted to treat IBD through intracolonic administration of 
specific miRNAs in the form of nanoparticle. This review summarizes the latest findings on the role of miRNAs 
in the pathogenesis, diagnosis, and treatment of IBD. 
Key words: inflammatory bowel diseases; Crohn’s disease; ulcerative colitis; microRNAs 
Introduction 
Inflammatory bowel disease (IBD) is a complex 
and multifactorial condition characterized by chronic 
gastrointestinal tract inflammation. There are two 
main forms of IBD: Crohn’s disease (CD) and 
ulcerative colitis (UC). CD is manifested as patchy 
transmural inflammatory patterns that affect all layers 
of the intestinal wall in any portion of the 
gastrointestinal tract, whereas UC is limited to the 
innermost layers of the mucosa in the large intestine. 
CD and UC mainly affect young people, causing 
bloody diarrhea, abdominal pain, malabsorption, 
fatigue, and impaired quality of life [1]. Long-lasting 
inflammation also increases the risk of colorectal 
cancer in patients with IBD, which has a mortality rate 
of 10-15% [2]. 
Rapid modernization and urbanization seem to 
be related to the increasing incidence of IBD, which 









in developed nations [3, 4]; however, the exact 
pathogenesis of IBD remains poorly understood. 
Based on speculations, IBD is presumed to be the 
result of complex interactions among genetic, 
microbial, and environmental factors [1]. Genome- 
wide association studies (GWASs) have identified the 
genetic susceptibility loci for IBD, and more than 240 
of these loci have been reported [5-8]. Substantial 
differences have been found between different ethnic 
groups [9, 10]. Moreover, the existence of IBD 
susceptibility mutations is not sufficient to explain the 
entire disruption of intestinal homeostasis; this is 
because twin studies revealed low concordance 
between genetic variations and clinical presentation of 
the disease [11]. The role of the microbiome and 
lifestyle factors in the pathogenesis of IBD is 
unquestionable; however, these conditions only cause 
disease in genetically susceptible individuals [12]. 
Recent molecular research has shown that 
microRNAs (miRNAs or miR-) play important roles in 
the pathophysiology of IBD [13]. miRNAs are 
evolutionarily conserved, endogenous, single- 
stranded, non-coding RNAs that bind to the 3’ 
untranslated region (UTR), 5’ UTR, or partially 
translated region of a target mRNA, inhibiting mRNA 
translation and blocking its expression [14]. miRNAs 
are major regulators of cell function and homeostasis, 
and their abnormal activity has been demonstrated in 
various diseases, including IBD. Thus, novel 
treatment options could be developed to alter 
imbalances in miRNA expression by targeting certain 
molecular pathways [15]. In this study, we evaluated 
the role of miRNAs in IBD by examining published 
results of studies conducted in the past 2-3 years and 
suggest the clinical potential of miRNAs as 
biomarkers and/or new therapeutic strategies for 
IBD. 
Biosynthesis of microRNA 
miRNAs are small, 18-21 nucleotide-long, 
evolutionarily conserved RNA molecules involved in 
the regulation of gene expression. The primary 
nuclear transcripts of miRNAs, or pri-miRNAs, are 
typically a few thousand nucleotides long and are 
located in introns, exons, or intergenic regions of the 
human genome. Pri-miRNAs are processed into 70 
nucleotide-long, stem-loop structured pre-miRNAs 
by the RNAse-3-type enzyme Drosha. Pre-miRNAs 
are then translocated to the cytosol from the nucleus 
and cleaved by the endoribonuclease Dicer. The 
remaining miRNA duplex binds with Argonaute to 
form an RNA-induced silencing complex (RISC). The 
guidance strand directs the RISC to the 
complementary region in the 3'-UTR of the target 
mRNA, and the RISC makes post-transcriptional 
modifications. When an exact match is found, the 
target mRNA is degraded; however, when an 
incomplete match occurs, translation is destabilized 
[14]. Figure 1 briefly summarizes the biosynthesis of 
miRNAs and their mechanisms of action. 
The seed region responsible for identifying 
target mRNAs is a 6 nucleotide-long sequence from 
the 2nd to the 7th nucleotide of the miRNA. Based on 
similar seed sequences, miRNAs are classified into 
miRNA families. Members of a given miRNA family 
share almost the same pool of mRNAs as their target 
as they possess the same seed region. Numerous 
miRNAs form clusters in the genome and are 
transcribed as one common pri-miRNA; therefore, 
their transcription is regulated simultaneously. 
Notably, the role of miRNAs is redundant; multiple 
different miRNAs can control a single mRNA, and a 
given miRNA can inhibit numerous mRNAs. miRNA 
regulation does not act as a switch; rather, it functions 
as a synchronized tuner of gene expression [16]. 
 
 
Figure 1. Biosynthesis of miRNA and the mechanism of action. miRNA: microRNA; RISC: RNA-induced silencing complex. 






Figure 2. Intracellular interactions in intestinal homeostasis and inflammation. In intestinal homeostasis, commensal bacteria and dietary metabolites, such as RA and AhR ligands, 
induce immune tolerance through the action of Treg cells and anti-inflammatory cytokines, including IL-10 and TGF-β1. Various immune cells are recruited into the intestinal 
lamina propria but are not activated. However, IgA produced by plasma cells, and anti-microbial peptides, including REG3 and defensin, which are secreted from ILC3 and Th17 
cells, prevent the pathogenic colonization of intestinal bacteria and invasion through the intestinal epithelium. In intestinal inflammation, direct invasion of commensal or 
pathogenic bacteria through the broken intestinal barrier causes inflammatory responses. Various immune cells and cytokines induce inflammatory reactions and augment 
anti-microbial activity. AhR: aryl hydrocarbon receptor; IFN: interferon; IL-: interleukin; ILC: innate lymphoid cell; NK T cell: natural killer T cell; PMN: polymorphonuclear 
leukocyte; RA: retinoic acid; REG3: Regenerating islet-derived protein 3; TGF β1: transforming growth factor β1; Th1: T helper type 1; Th2: T helper type 2; Th17: T helper type 
17; TNF-α: tumor necrosis factor-α; Treg cell: regulatory T cell. 
 
Brief description of the pathophysiology 
of IBD 
Commensal bacteria are essential components in 
the maintenance of intestinal homeostasis. They 
provide essential nutrients, assist in energy 
metabolism, and suppress the growth of pathogenic 
bacteria by competitive inhibition in the intestine [17]. 
Nevertheless, they can cause opportunistic infections 
and are under the surveillance of host immunity. 
Consequently, the human immune system has 
adapted to maintain a commensal relationship by 
establishing a balance between immune suppression 
and activation. The intestine is continuously exposed 
to large amounts of toxins and antigenic proteins from 
ingested foods. Therefore, a high level of immune 
tolerance is essential for intestinal homeostasis [18]. 
However, well-controlled immune responses can be 
aberrantly activated by altered states of intestinal 
bacteria or the intestinal barrier, which are two 
important factors that maintain immune tolerance. 
From our perspective, a disruption in physiological 
balance can result in the development of IBD (Figure 
2). 
Many immune cells, such as neutrophils, 
dendritic cells, macrophages, and lymphoid cells, 
reside in the intestinal epithelium and the underlying 
lamina propria. These cells are regulated by immune 
tolerance mechanisms. When macrophages 
phagocytose the antigen from commensal bacteria, 
interleukin (IL)-10 is secreted from macrophages [19], 
resulting in the promotion of the response of a cluster 
of differentiation 4+ (CD4+) Treg cells to suppress 
inflammatory T cell reactions. CD4+ Treg cells 
produce IL-10 and transforming growth factor β1 
(TGF-β1) to change the subtype of macrophages into 
an anti-inflammatory phenotype and to facilitate 
peripheral development of Treg cells [20]. Serum 
amyloid A is an important acute reactant protein 
produced in the intestine and liver. A previous study 
demonstrated that serum amyloid A had a higher 
increase in the presence of intestinal microbiota than 
in the germ-free state. Serum amyloid A enhances the 
recruitment of neutrophils to the intestine and 
increases pro-inflammatory gene expression in 
neutrophils, but decreases bactericidal capability and 
inflammatory tones [21, 22]. These contradictory 
responses would not damage the intestinal microbiota 
during the prevention of opportunistic infections by 
commensal bacteria. CD4+ T cells secrete IL-21 and 
TGF-β1 to stimulate immunoglobulin (Ig) class 
switching in B cells. The secreted IgAs bind to 
commensal bacteria in the intestinal lumen, which 





prevents bacteria from invading the intestinal 
epithelium, and suppress the inflammatory reaction 
of the intestinal barrier against commensal bacteria 
[23]. Retinoic acid, a metabolite of vitamin A, is an 
important nutritional factor that is closely related to 
the immune response. Retinoic acid plays an 
important role in maintaining intestinal homeostasis, 
specifically inducing intestinal immune tolerance 
through the actions of CD103+ dendritic cells and 
innate lymphoid cells (ILCs)3 [24]. However, based on 
a recent study, commensal bacteria reduced retinoic 
acid and IL-22 by inhibiting retinol dehydrogenase 7 
(Rdh7) in intestinal epithelial cells. Consequently, the 
anti-microbial reaction was downregulated, and a 
symbiotic state could be maintained [25]. Such 
findings indicate that retinoic acid has both 
tolerogenic capacity and antimicrobial activity. Thus, 
intestinal immune tolerance does not simply mean a 
decrease in intestinal immunity, but rather a balanced 
state in which anti-inflammatory and anti-microbial 
activities coexist. The aryl hydrocarbon receptor 
(AhR) is a transcription factor that induces 
anti-inflammatory reactions at the gene level. 
Previous studies have indicated that AhR reduces 
intestinal inflammation through anti-inflammatory 
mediators, such as IL-10 and IL-22. Several AhR 
ligands exist in the intestine, the majority of which are 
metabolites of commensal bacteria. Therefore, 
intestinal microbiota contributes to AhR-induced 
immunomodulation [26, 27]. Taken together, host 
immunity has dual effects on the intestinal microbiota 
to maintain intestinal homeostasis. The intestinal 
immune system should maintain an appropriate 
balance between inflammatory and anti-inflammatory 
responses. Dysbiosis, which is an imbalance in 
microbes in the intestine, disrupts intestinal 
homeostasis and should thus be considered as a major 
cause of IBD [28]. 
The intestinal epithelium is one of the key 
components that sustain homeostasis of the intestine. 
The membranous barrier separates intestinal germs 
from the submucosal lymphoid tissue to prevent 
inflammatory responses and integrates molecular 
signals from dietary metabolites, commensal bacteria, 
and pathogens to regulate immune reactions [29]. 
Resident lymphoid cells, such as NK T cells, γδ T cells, 
ILCs, intraepithelial lymphocytes, and CD8+ 
mucosal-associated invariant T cells produce IL-6, 
IL-17, and IL-22 to activate the signal transducer and 
activator of transcription (STAT) 3 pathway in 
response to disruption of the intestinal barrier. The 
STAT3 pathway promotes the recovery of barrier 
function and increases mucus secretion and epithelial 
repair [30]. Macrophages secrete type I interferon 
(IFN) and activate STAT1 and STAT2 pathways to 
prevent epithelial apoptosis, promote epithelial 
differentiation, and maintain the integrity of the 
intercellular barrier [31]. CD4+ T cells produce IL-17 
and IL-22 in response to IL-23 and serum amyloid A, 
which results in the activation of the STAT3 pathway 
in the epithelium [32]. These interactions enhance the 
intestinal barrier against pathogenic luminal bacteria. 
When the mucus barrier is broken, permeability 
through the epithelium increases. These situations are 
mostly due to the dysfunction of the mucosal barrier 
itself, or inflammatory damage. Mucous membrane 
disorder, tight junction disorder, increased intestinal 
permeability, and increased binding of bacteria to 
epithelial cells can induce intestinal inflammation. 
Penetration of intestinal bacteria, including intestinal 
microbiota, into the lamina propria leads to 
recognition by phagocytes and the production of 
inflammatory cytokines by macrophages. 
Macrophages secrete IL-1β to promote the 
differentiation of CD4+ T cells into T helper 17 (Th17) 
cells and the production of IFN-γ [33, 34]. Damaged 
epithelium releases IL-18, which disrupts goblet cell 
maturation and impairs its function, leading to further 
damage of the membranous barrier [35]. Macrophages 
enhance the survival of pro-inflammatory T cells and 
stimulate epithelial apoptosis through the tumor 
necrosis factor-α (TNF‐α) signaling pathway [36, 37]. 
IL-6 from macrophages and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) from ILCs recruit 
polymorphonuclear leukocytes, which secrete 
pro-inflammatory cytokines for pathogenic T cell 
responses [38-40]. Repeated cycles of dysregulated 
immune responses result in chronic intestinal injury 
and fibrotic remodeling in patients with IBD [41]. 
IBD is a multifactorial disease. Although 
dysbiosis of commensal bacteria and breakdown of 
the intestinal barrier are considered as major 
pathological mechanisms in the development of IBD, 
other important factors such as genetic aberrations 
also contribute to its development. In this regard, 
miRNAs are an emerging risk factor for IBD. miRNAs 
are involved in the maintenance of intestinal barrier 
integrity, as well as a large number of intracellular 
signaling pathways involved in inflammatory or 
anti-inflammatory actions [42]. 
Role of miRNAs in the pathophysiology 
of IBD 
miRNAs have been reported to be associated 
with several pathophysiological factors of IBD. 
miRNAs affect the intestinal barrier and 
inflammatory reactions through various pathological 
mechanisms. The pathogenic roles of miRNAs in IBD 
are summarized in Table 1. 





Table 1. Roles of miRNAs in the pathogenesis of inflammatory bowel disease 
miRNAs Targets Functions Ref. 
miRNAs that weaken the intestinal barrier  
miR-21 PTEN/PI3K/Akt 
pathway 
Increases the paracellular permeability of the intestinal epithelium [49] 
miR-122a EGFR Enhances the expression of zonulin and increases epithelial permeability [48] 
miR-191a, -212 ZO-1 Reduce the expression of ZO-1 [44, 45] 
miR-675 Cadherin E, ZO-1 Destabilizes the mRNA of cadherin E and ZO-1 [46] 
miR-874 Aquaporin 3 Decreases the expression of aquaporin 3 [47] 
miRNAs that strengthen the intestinal barrier  
miR-93 PTK6 Reduces the expression of PTK6, and its downregulation attenuates epithelial injury [51] 
miR-200b c-Jun, MLCK Decreases epithelial damage induced by TNF-α in the intestinal epithelium [50] 
miRNAs that increase inflammation   
miR-21 MIP2, TNF-α Increases the level of MIP2 and TNF-α [52] 
miR-124 AhR Suppresses AhR expression and increases pro-inflammatory cytokine production [53] 
miRNAs that decrease inflammation   
miR-10a IL-12/23p40 Downregulates the expression of IL-12/23p40 and Th1/Th17 cell responses [56] 
miR-141 CXCL12β Inhibits CXCL12β-mediated leukocyte migration [57] 
miR-320 NOD2 Decreases the expression of NOD2 [55] 
miRNAs that enhance autophagy   
miR-346 Vitamin-D receptor, 
GSK3B 
Downregulates the expression of GSK3B, which increases ATG16L1 [62] 
miR-665 XBP1, ORMDL3 Represses XBP1 and ORMDL3 expression [63] 
miRNAs that inhibit autophagy   
miR-20a ATG16L1, SQSTM1 Downregulates BECN1, ATG16L1, and SQSTM1 [64] 
miR-30C ATG5, ATG16L1 Reduces the level of ATG5 and ATG16L1 [65] 
miR-93, -106B ATG16L1, PTEN Suppress ATG16L1 expression and PTEN activity [66, 67] 
miR-122 NOD2, NF-κB Inhibits NOD2 activity and increases NF-κB [69] 
miR-130a p-mTOR Increases the level of p-mTOR [71] 
miR-132, -223 FOXO3a Downregulate FOXO3a, which enhances NF-κB signaling [72] 
miR-142-3p ATG16L1 Decreases ATG16L1 mRNA and protein levels [68] 
miR-146b SIAH2, FOXO3 Decreases SIAH2 and FOXO3 expression and activates the NF-κB pathway [74] 
miR-155 SHIP-1, FOXO3a Increases Akt activity by decreasing SHIP-1, downregulates FOXO3a and enhances the NF-κB pathway [75, 76] 
miR-192 NOD2, NF-κB Downregulates NOD2 expression and inhibits NF-κB activity [70] 
miR-196 LC3-II Inhibits the accumulation of LC3-II [77] 
miR-320 NOD2 Reduces NOD2 expression [55] 
 
miRNAs and the intestinal barrier in IBD 
Disrupted intestinal membranes are one of the 
most significant factors in the pathogenesis of IBD. 
TNF-α is known to be a major pro-inflammatory 
cytokine in the pathogenesis of IBD. Therefore, 
several in vitro experiments have been conducted 
using intestinal epithelial cells to induce injury by 
TNF-α [43]. miR-191a and miR-212 are known to 
damage intestinal barriers. In fact, in vitro studies 
have shown that their mimics downregulate the 
expression of zonula occludens (ZO)-1, one of the 
major components of the tight junction between the 
intestinal epithelium [44, 45]. By measuring the 
binding of miR-675 in colon cells in vitro, Zou et al. 
found that miR-675 destabilized the mRNA of ZO-1 
and cadherin E, causing reduced expression of key 
molecules for intercellular tight junctions [46]. 
Aquaporin 3 is another important protein in the 
intestinal membrane. The overexpression of miR-874 
in vitro induced by pre-miR-874 transfection in 
intestinal epithelial cells was demonstrated to 
decrease the expression of aquaporin 3 [47]. 
Epidermal growth factor receptor (EGFR) was 
identified as the target gene of miR-122a. The 
overexpression of miR-122a was found to increase 
zonulin expression and intestinal permeability [48]. 
Further, the overexpression of miR-21 in vitro was 
found to cause an increase in intestinal barrier defects 
and was suggested to target the phosphatase and 
tensin homolog (PTEN)/PI3K (phosphoinositide 
3-kinase)/Akt signaling pathway to enhance the 
paracellular permeability of the intestinal epithelium 
[49]. As the miR-21 mimic suppressed the level of 
PTEN and increased the level of phospho-Akt (p-Akt) 
in vitro, Zhang et al. reported the impairing of 
intestinal permeability through the PTEN/PI3K/Akt 
pathway as a potential mechanism [49]. 
Some miRNAs have been reported to strengthen 
the intestinal barrier. Transfection of the miR-200b 
precursor in TNF-α-treated intestinal epithelium in 
vitro inhibited the damage to trans-epithelial electrical 
resistance and intercellular tight junctions. Further, 
c-Jun and myosin light chain kinase (MLCK) were 
demonstrated to be the targets of miR-200b [50]. 
Haines et al. revealed that silencing the expression of 
protein tyrosine kinase 6 (PTK6) with miR-93 in the 
intestinal epithelium increased the resistance to 
TNF-α-induced injury [51]. 





miRNAs and immune response in IBD 
miRNAs are known to contribute to the 
immunological reactions that lead to IBD. Shi et al. 
compared miR-21 knockout mice to wild-type mice 
after the induction of intestinal damage by dextran 
sulfate sodium (DSS); miR-21 knockout mice 
demonstrated reduced weight loss, intestinal 
inflammation (confirmed by histopathology), serum 
leukocyte levels, and TNF-α and macrophage 
inflammatory protein 2 (MIP2) levels in colon culture 
supernatants compared to wild-type mice [52]. 
miR-124 was reported to target the 3’-UTR of AhR to 
suppress its expression in Caco-2 cells and HT-29 cells 
in vitro [53]. Intracolonic administration of miR-124 
inhibitors and precursors to 2,4,6-trinitrobenzen acid 
(TNBS)-induced colitis mice was found to alleviate 
and aggravate intestinal inflammation, respectively 
[53]. 
Some miRNAs have been reported to suppress 
intestinal inflammation. Nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) 
is one of the genes clearly associated with CD [54]. In 
fact, Pierdomenico et al. reported its relationship with 
miR-320 [55]. HT29 cells transfected with exogenous 
miR-320 displayed a downregulated expression of 
NOD2, while miR-320 inhibitor increased NOD2 
expression as well as its downstream signaling 
pathway, leading to nuclear factor κB (NF-κB) and 
inflammatory cytokines [55]. Wu et al. used human 
monocyte-derived dendritic cells and CD4+ T cells 
isolated from the peripheral blood of IBD patients 
treated with the miR-10a precursor. The transfection 
caused decreased expression of IL-12/23p40 (p40 
subunit of IL-12 and IL-23) in dendritic cells and 
suppression of IFN-γ, TNF-α, and IL-17A in CD4+ T 
cells, suggesting inhibited differentiation into Th1 and 
Th17 cells [56]. C-X-C motif chemokine ligand 12β 
(CXCL12β) is an important mediator of leukocyte 
migration. Huang et al. used TNBS-induced colitis 
mice, IL-10 knockout colitis mice, and colon biopsy 
samples of CD patients to identify an inverse 
relationship between miR-141 expression and 
CXCL12β levels [57]. Intracolonic administration of 
miR-141 precursors and inhibitors to both 
TNBS-colitis mice and IL-10 knockout mice alleviated 
and aggravated colitis, respectively [57]. 
miRNAs and autophagy in IBD 
Autophagy is a cellular response that degrades 
and recycles internal structures, such as organelles 
and macromolecules. Therefore, its purpose is to 
maintain cell homeostasis and regulate inflammatory 
responses [58]. Defects in autophagy can cause 
epithelial dysfunction and immune disruption, which 
play important roles in the pathogenesis of IBD [59]. 
Recent studies suggest that miRNAs target 
autophagy-susceptibility genes to regulate intestinal 
autophagy and control intestinal inflammation in IBD 
[60]. ATG16L1 is an autophagy-related gene that 
forms autophagosomes during autophagy [61]. 
miR-346 was reported to downregulate the expression 
of the vitamin D receptor, glycogen synthase kinase 3 
beta (GSK3B), to increase the level of ATG16L1 in 
colon biopsy samples of IBD patients [62]. miR-665 
represses X-box binding protein 1 (XBP1) and 
ORMDL sphingolipid biosynthesis regulator 3 
(ORMDL3), which also stimulates autophagy [63]. 
Many miRNAs are known to inhibit autophagy. 
miR-20a downregulates Beclin 1 (BECN1), ATG16L1, 
and sequestosome 1 (SQSTM1), which collectively 
slows down autophagy [64]. miR-30C [65], miR-93, 
miR-106B [66, 67], and miR-142-3p [68] also target the 
expression of ATG16L1 to prevent autophagy. 
miR-122 [69], miR-192 [70], and miR-320 [55] were 
found to decrease the activity of NOD2 to block 
autophagy. miR-130a increases the level of 
phosphorylated mammalian target of rapamycin 
(p-mTOR) [71], while miR-132, miR-223, miR-146b, 
and miR-155 reduce Forkhead box class O3 (FOXO3 
or FOXO3a) to inhibit autophagy [72-76]. miR-196 
blocks the accumulation of the lipid-modified form of 
microtubule-associated protein 1A/1B-light chain 3 
(LC3-II) to prevent autophagy [77]. 
Role of miRNAs in IBD diagnosis 
Diagnosis and evaluation of IBD have always 
been challenging. IBD is diagnosed based on clinical 
manifestations and endoscopy with histopathological 
examination [78]; however, various clinical 
manifestations make diagnosis difficult, and 
endoscopy with histopathology requires the expertise 
of clinicians [79]. As miRNAs are known to be 
associated with the pathogenesis of IBD, several 
studies have suggested that miRNAs are non-invasive 
and inexpensive biomarkers. A list of possible 
candidates is provided in Table 2. 
miRNA signature from the colon tissues of IBD 
patients 
Some studies found abnormal elevation of 
miRNA levels in the mucosal tissues of UC patients 
compared to those of healthy controls. In fact, Wu et 
al. found that miR-16, miR-21, miR-23a, miR-24, 
miR-29a, miR-126, miR-195, and let-7f were 
upregulated in active UC patients compared to 
healthy controls [80]. By comparing the colonic 
mucosa of UC patients and healthy controls, Fasseu et 
al. showed that miR-7, miR-26a, miR-29a, miR-29b, 
miR-31, miR-126* (the complement of miR-126), 
miR-127-3p, miR-135b, and miR-324-3p were 





increased in the inflamed mucosa of UC patients [81]. 
Takagi et al. found increased levels of miR-21, 
miR-155, miR-923, let-7a, let-7c, let-7d, and let-7g in 
colon biopsy specimens of active UC patients 
compared to healthy controls [82]. miR-126 [83] and 
miR-150 [84] were elevated in the colonic mucosa of 
patients with active UC compared to controls. Frozen 
biopsy samples of distal colectomy from UC patients 
were found to have significant increases in miR-31, 
miR-146a, miR-206, and miR-424 levels [85]. Coskun 
et al. identified increases in miR-20b, miR-26b, 
miR-98, miR-99a, and miR-203 levels in colon biopsy 
samples of active UC patients compared to healthy 
controls, inactive UC patients, and CD patients [86]. 
 
Table 2. miRNA signatures in inflammatory bowel disease 
Sample 
type 
Expression miRNAs Ref. 
Ulcerative colitis vs. healthy controls  
Mucosal 
tissue 
Upregulated miR-7, miR-16, miR-20b, miR-21, miR-23a, 
miR-24, miR-26a, miR-26b, miR-29a, miR-29b, 
miR-31, miR-98, miR-99a, miR-126, miR-126*, 
miR-127-3p, miR-135b, miR-146a, miR-150, 
miR-155, miR-195, miR-203, miR-206, 
miR-324-3p, miR-424, miR-923, let-7a, let-7c, 
let-7d, let-7f, let-7g 
[80-86] 
Downregulated miR-141, miR-188-5p, miR-192, miR-215, 





Upregulated miR-16, miR-19a, miR-21†, miR-28-5p, 
miR-101, miR-103-2, miR-142-5p, miR-151-5p, 
miR-155, miR-188-5p, miR-199a-5p, miR-223, 
miR-340, miR-362-3p, miR-375, miR-378, 
miR-422a, miR-494, miR-500, miR-501-5p, 




Downregulated miR-21†, miR-31, miR-146a, miR-505 [88, 99] 
Crohn’s disease vs. healthy controls  
Mucosal 
tissues 
Upregulated miR-9, miR-21, miR-22, miR-26a, miR-29b, 
miR-29c, miR-30b, miR-31, miR-34c-5p, 
miR-101, miR-106a, miR-106b, miR-126*, 
miR-127-3p, miR-130a, miR-133b, miR-146a, 
miR-146b-5p, miR-150, miR-155, miR-181c, 





Downregulated miR-7, miR-375 [88, 89] 
Peripheral 
blood 
Upregulated miR-16, miR-20a‡, miR-21‡, miR-23a, 
miR-29a, miR-30e‡, miR-93‡, miR-101, 
miR-106a, miR-107, miR-126, miR-140‡, 
miR-191, miR-192‡, miR-195‡, miR-199a-5p, 




Downregulated miR-21, miR-31, miR-146a, miR-155 [88] 
*Complementary miRNA, †Upregulation from [98] and downregulation from [88], 
‡From pediatric patients [101]. 
 
 
Decreased levels of miR-188-5p, miR-215, 
miR-320a, and miR-346 were observed in the inflamed 
mucosa of UC patients compared to controls [81]. 
miR-141 was found to be downregulated in the 
colonic mucosa of patients with active UC compared 
to healthy controls [87]. miR-192, miR-375, and 
miR-422b were downregulated in colon biopsy 
samples from patients with active UC [80]. 
The mucosal tissue samples of patients with 
active CD had aberrant expression of miRNAs 
compared to controls. Fasseu et al. reported that 
miR-9, miR-21, miR-22, miR-26a, miR-29b, miR-29c, 
miR-30b, miR-31, miR-34c-5p, miR-106a, miR-126*, 
miR-127-3p, miR-130a, miR-133b, miR-146a, 
miR-146b-5p, miR-150, miR-155, miR-181c, miR-196a, 
miR-324-3p, and miR-375 were elevated in the 
inflamed mucosa of CD patients relative to levels in 
healthy controls [81]. Further, Lin et al. showed that 
miR-31, miR-146a, miR-206, and miR-424 were 
increased in frozen biopsy samples of CD patients 
compared to controls, similar to that found in UC 
patients [85]. miR-106b [66] and miR-196 [77] were 
upregulated in the intestinal epithelium of patients 
with active CD compared to controls. Schaefer et al. 
found an increase in miR-31, miR-101, and miR-146a 
levels in colon biopsy samples from CD patients 
compared to healthy controls [88]. Further, miR-7 and 
miR-375 levels were decreased in the actively 
inflamed colonic mucosa of CD patients [88, 89]. 
Among the miRNAs included in the differential 
analysis of IBD colon tissues, miR-21, miR-31, and 
miR-141 are suggested to be valuable targets for the 
diagnosis of IBD. miR-21 is known to be an important 
factor in the pathogenesis of IBD as it modulates T-cell 
responses [90] and disrupts intercellular tight 
junctions in the intestinal epithelium [91]. miR-21 was 
found to be elevated in the mucosal tissue of both UC 
and CD [92, 93], and the knockout of miR-21 in a 
mouse model of DSS-induced colitis inhibited the 
inflammatory response and increased survival rate, 
indicating the importance of miR-21 in IBD [52]. 
miR-31 was upregulated in the colon tissues of both 
UC and CD patients [88]; this miRNA is known to 
target IL-25 to stimulate the Th1/Th17-mediated 
pro-inflammatory molecular pathway in mouse colitis 
models [94]. miR-31 has also been suggested to be 
capable of distinguishing IBD from microscopic 
colitis, as its expression is elevated in IBD compared 
to microscopic colitis [95]. miR-141 inhibits CXCL5 
and CXCL12β, and its downregulation in IBD is 
expected to stimulate leukocyte recruitment and the 
consequent inflammatory response. A decrease in 
miR-141 was observed in the colon tissues of patients 
with UC [87]. 
Furthermore, useful findings have been obtained 
from the analysis of colon samples from patients with 
IBD. After acquiring rectal biopsy samples of UC and 
CD patients, Zham et al. found that miR-24 was 
increased in UC samples compared to CD samples, 
with a sensitivity of 83.3% and specificity of 85.7% as a 
diagnostic biomarker [96]. Jeremy et al. used matched 
colon biopsies from UC and CD patients to compare 
endoscopically involved regions with endoscopically 
uninvolved regions of each patient. miR-21, miR-31, 
miR-101, miR-142-3p, miR-142-5p, miR-155, miR-223, 
miR-375, and miR-494 levels were elevated in active 





CD lesions compared to inactive regions; miR-21, 
miR-101, miR-142-5p, miR-146a, miR-155, and 
miR-223 levels were higher in active UC lesions than 
in inactive regions [88]. Guo et al. compared inflamed 
and non-inflamed mucosal samples of the terminal 
ileum of active CD patients and found that 
miR-124-3p and miR-192-5p levels were decreased, 
while miR-361-3p was upregulated in the inflamed 
mucosa of CD patients [97]. 
miRNA signature from the peripheral blood of 
IBD patients 
As the acquisition of colon tissues requires a 
relatively invasive procedure compared to blood 
sampling, some studies have attempted to identify 
miRNA signatures from the peripheral blood of 
patients with active IBD. Paraskevi et al. reported 
increased levels of miR-16, miR-23a, miR-29a, 
miR-106a, miR-107, miR-126, miR-191, miR-199a-5p, 
miR-200c, miR-362-3p, and miR-532-3p in the blood of 
CD patients compared to healthy controls, and 
elevated levels of miR-16, miR-21, miR-28-5p, 
miR-151-5p, miR-155, and miR-199a-5p in the blood of 
UC patients compared to controls [98]. Wu et al. 
found increased levels of miR-199a-5p, miR-340*, 
miR-362-3p, miR-532-3p, and miRplus-E1271, and 
decreased levels of miR-149* and miRplus-F1065 in 
the blood of patients with active CD compared to 
controls [99]. The levels of miR-28-5p, miR-103-2*, 
miR-151-5p, miR-199a-5p, miR-340*, miR-362-3p, 
miR-532-3p, and miRplus-E1271 were increased, 
while that of miR-505* was decreased in the 
peripheral blood samples of active UC patients 
compared to healthy controls [99]. By measuring 
miRNAs from the platelet fraction, Duttagupta et al. 
found increased levels of miR-188-5p, miR-378, 
miR-422a, miR-500, miR-501-5p, miR-769-5p, and 
miR-874 in blood samples from UC patients 
compared to controls [100]. Schaefer et al. collected 
peripheral blood from UC and CD patients with 
normal controls and reported elevated levels of 
miR-19a, miR-101, miR-142-5p, miR-223, miR-375, and 
miR-494, and reduced levels of miR-21, miR-31, and 
miR-146a in the blood samples of UC patients 
compared to healthy controls; the levels of miR-101 
and miR-375 were increased, while those of miR-21, 
miR-31, miR-146a, and miR-155 were decreased in the 
whole blood of CD patients compared to controls [88]. 
Zahm et al. reported elevated levels of miR-16, 
miR-20a, miR-21, miR-30e, miR-93, miR-106a, 
miR-140, miR-192, miR-195, and miR-484 in serum 
samples from pediatric CD patients compared to 
normal controls [101]. 
Viennois et al. found that the levels of 
miR-29b-3p, miR-122-5p, miR-146a-3p, miR-150-5p, 
miR-192-5p, miR-194-5p, and miR-375-3p were 
elevated in the serum of IL10 (-/-) mice, which 
distinguished peripheral blood samples from UC 
patients and healthy controls with 83.3% sensitivity 
[102]. Wu et al. reported that the serum levels of eight 
miRNAs (miR-28, miR-103-2*, miR-149*, miR-151, 
miR-340*, miR-505*, miR-532, and miR-plus-E1153) 
could be used to distinguish UC from CD [99]. Jensen 
et al. used reverse-transcription polymerase chain 
reaction (RT-PCR) to measure the miRNA levels in 
serum samples of CD patients and healthy controls. 
Thereafter, they proposed that a decrease in serum 
miR-16b could be used to diagnose CD, which yielded 
an area under the curve of 65% [103]. Zham et al. 
measured 11 miRNAs (miR-16, miR-20a, miR-21, 
miR-30e, miR-93, miR-106a, miR-140, miR-192, 
miR-195, miR-484, and let7b) in serum samples from 
CD patients and healthy controls and reported that 
their elevation served as a diagnostic marker for CD 
with a sensitivity of 70%–83% and specificity of 75%–
101%. By performing miRNA microarray analysis of 
the saliva from UC patients, CD patients, and healthy 
controls, Schaefer et al. found increases in the levels of 
miR-21, miR-31, and miR-142-3p and a decrease in 
miR-142-5p levels in UC patients, while saliva 
samples from CD patients showed elevated miR-26a 
and miR-101 levels compared to controls [88]. 
Gallo et al. suggested that miRNAs in human 
saliva and serum samples mainly exist in the form of 
exosomes (encapsulated microvesicles) [104]. Vickers 
et al. presented evidence that miRNAs are transported 
by high-density lipoprotein (HDL) to recipient cells 
[105]. Exosomes and HDL can protect miRNAs from 
ribonucleases in the blood, which makes it easier to 
measure miRNA levels in serum samples. 
Role of miRNAs in the treatment of IBD 
As in vitro studies have confirmed the 
importance of miRNAs in the pathophysiology of 
IBD, some researchers have attempted to 
administered miRNAs in vivo to mice with 
experimental colitis. Intracolonic administration of 
miRNA mimic molecules and antagonists led to the 
overexpression and inhibition of miRNA expression, 
respectively [106]. 
Nanoparticle-mediated approach 
Tian et al. found that the delivery of the miR-31 
mimic into the colon of DSS-colitis mice alleviated the 
inflammatory response. miR-31 was bound to 
encapsulating microspheres and administered via 
enema, resulting in a slower loss of body weight and 
colon length, as well as increased epithelial 
proliferation and reduced inflammation, as confirmed 
by colon biopsy [107]. Neudecker et al. also reported 





the attenuation of occult bleeding, weight loss, and 
edema in DSS-colitis mice after intracolonic 
administration of synthetic murine miR-223 mimetic 
in nanoparticle lipid emulsion [108]. The intracolonic 
administration of miR-141 precursors in mice with 
TNBS-induced colitis resulted in a decrease in 
CXCL12β expression and leukocyte infiltration in the 
intestine [57]. miR-146b was also found to alleviate 
intestinal inflammation when administered into the 
peritoneum of DSS-induced colitis mice with 
expression vectors [74]. By using a mouse model of 
TNBS-induced colitis, Cheng et al. demonstrated that 
the intracolonic administration of pre-miR-19b can 
suppress the inflammatory process, with in vitro 
results suggesting that miR-19b inhibits suppressor of 
cytokine signaling 3 (SOCS3) to reduce inflammation 
of the intestinal epithelium in IBD [109]. miR-200b 
bound to microvesicles was administered to intestinal 
epithelial cells in vitro and the colon of TNBS-colitis 
mice in vivo; this administration resulted in the 
attenuation of intestinal fibrosis with suppression of 
TGF-β1 mediated epithelium-to-mesenchyme 
transition [110]. 
Other routes of administration have been 
attempted to deliver miRNA mimic molecules to mice 
with colitis. Zhang et al. purified nanoparticles from 
edible ginger and found that their oral administration 
by colitis mice reduced the severity of colitis and 
promoted wound healing. The nanoparticles 
contained around 125 miRNAs. Further, the colon 
samples of mice administered the nanoparticles had a 
decrease in pro-inflammatory cytokines (TNF-α, IL-6, 
and IL-1β), increase in anti-inflammatory cytokines 
(IL-10 and IL-22), and increase in the proliferation of 
the epithelium based on the biopsy [111]. Fukata et al. 
attempted to intravenously administer miR-29a-3p 
and miR-29b-3p bound to supercarbonate apatite. 
These researchers reported a decrease in the 
inflammatory response in DSS-colitis mice and 
revealed that the subcutaneous injection of miR-29b 
bound to supercarbonate apatite inhibited the 
immune response by targeting CD11c+ dendritic cells 
in a DSS-colitis model [112]. 
Conclusion 
IBD is a multifactorial disease associated with 
environmental and genetic factors. Dysbiosis of 
commensal bacteria and breakdown of the intestinal 
barrier integrity are considered to be major factors in 
the development of IBD. However, recent studies 
have indicated that genetic factors, including miRNA 
dysregulation, play a major role in the 
pathophysiology of IBD. Numerous miRNAs 
participate in the complex regulatory system of 
intestinal inflammation. Further, the number of 
molecular interactions seems to be uncountable; 
however, recent findings suggest the targeting of 
certain miRNAs as clinical biomarkers or treatment 
options. Additional in vivo studies should be 
conducted to validate data from in vitro studies and 
assess the practicality of manipulating miRNA 
expression in IBD. 
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